A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.
• Voluntary consent to participate in this study must be given (in writing)
• Japanese or non-Asian healthy men 18 to \< 55 years at the time of informed consent ( Japanese healthy men 65 to \< 80 years for the elderly cohort)
• BMI is within the specified range at screening
• Voluntary consent to participate in this study must be given (in writing)
• Japanese patients with essential hypertension, aged 18 to \<65 years at the time of informed consent
• BMI is within the specified range at screening
• Voluntary consent to participate in this study must be given (in writing)
• Japanese patients with essential hypertension, aged 18 to \<80 years at the time of informed consent
• BMI is within the specified range at screening